Tilsotolimod
- Generic Name
- Tilsotolimod
- Drug Type
- Biotech
- CAS Number
- 1948266-37-2
- Unique Ingredient Identifier
- G287IC9MH3
- Background
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 25
- Registration Number
- NCT04270864
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT04196283
- Locations
- 🇺🇸
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
🇺🇸Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- Drug: Saline (0.9% sodium chloride)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- A.J.M. van den Eertwegh
- Target Recruit Count
- 214
- Registration Number
- NCT04126876
- Locations
- 🇳🇱
VU Medical Centere, Amsterdam, Netherlands
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03865082
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Southern California/ Hoag Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Banner University Medical Center Tucson Campus, Tucson, Arizona, United States
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 481
- Registration Number
- NCT03445533
- Locations
- 🇩🇪
Universitatsklinikum Regensburg, Regensburg, Germany
🇫🇷CHU Amiens Picardie - Hopital Sud, Amiens, France
🇺🇸Sutter Health Sacramento, Sacramento, California, United States
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03052205
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale, Arizona, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02644967
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Icahn School Of Medicine at Mount Sinai, New York, New York, United States
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
- Conditions
- Hepatitis C, Treatment Naïve, Genotype 1 Patients
- Interventions
- Drug: Saline
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00990938
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00728936
- Locations
- 🇺🇸
Henry Ford Med Ctr- Columbus, Novi, Michigan, United States
🇵🇷Fundacion de Investigacion de Diego, Santurce, Puerto Rico
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.